SCHEMBL7531008

SCHEMBL7531008

CCc1ccc(Nc2ncccn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.56
NPC1 O15118 6/20 0.56
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
CYP2C19 P33261 1/20 0.55
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
MAPKAPK2 P49137 1/20 0.44
CXCR4 P61073 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4926432 0.80 ADRB2 (0.52)
SCHEMBL7460307 0.80 SYK (0.55)
SCHEMBL9837237 0.79 CYP1A2 (0.51) RAB9ANPC1CYP1A2CYP3A4CYP2D6
SCHEMBL14368037 0.79 GRM4 (0.56) PTGS1PTGS2SMN1; SMN2
SCHEMBL13185630 0.78 IKBKB (0.60) RAB9ANPC1KMT2AMEN1MAPKAPK2
SCHEMBL49571 0.78 RAB9A (0.55) RAB9ANPC1CYP1A2CYP3A4CYP2D6
SCHEMBL16432125 0.78 HPGD (0.61) RAB9ANPC1CYP1A2CYP3A4CYP2D6
SCHEMBL27028583 0.77 SYK (0.69) RAB9ANPC1HPGDALDH1A1KMT2A
SCHEMBL3786298 0.77 HPGD (0.54) RAB9ANPC1HPGDALDH1A1SMN1; SMN2
SCHEMBL15331048 0.77 NPC1 (0.49) RAB9ANPC1CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4308117-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION Université de Lausanne (CH) 2024-01-24 EP disclosed
WO-2022194953-A1 METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH HYPERMINERALIZATION Université de Lausanne (CH) 2022-09-22 WO disclosed
EP-0233461-B2 4,5,6-Substituted-2-pyrimidinamines AMERICAN CYANAMID CO (US) 2002-05-29 EP disclosed